Skip to content

Telemonitoring System for Improving Continuity of Care in Patients With Chronic Coronary Syndrome (TELSINCORC)

Usefulness of a Telemonitoring System to Optimize Continuity of Care From Cardiology to Primary Care in Patients With Chronic Coronary Syndrome

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05875311
Acronym
TELSINCORC
Enrollment
160
Registered
2023-05-25
Start date
2023-11-28
Completion date
2024-10-01
Last updated
2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Syndrome

Keywords

mobile health, Chronic coronary syndrome, cardiac rehabilitation, telerehabilitation, secondary prevention, exercise

Brief summary

In a randomized clinical trial, a comprehensive telerehabilitation system with a prolonged follow-up strategy demonstrated superiority over a control group with centre-based cardiac rehabilitation in terms of physical activity, VO2 max, adherence to a Mediterranean diet, lipid particle profile and cost-effectiveness. The aim of this study is to demonstrate an extension of the benefit to patients with chronic coronary syndrome in primary care.

Detailed description

The patients who have suffered an acute coronary event have a recurrence rate of 2.5% to 15.5% person-years during the first year. Control of cardiovascular risk factors can improve the prognosis of these patients. Following the results of a clinical trial to validate a comprehensive monitoring system called Cardioplan, with a prolonged monitoring strategy, The investigators aim to conduct a study in patients with chronic coronary syndrome in the primary care setting comparing a control group with standard follow-up and a 10-month telemonitored group. Four primary care centres will participate. Two health centres attend mainly a population with a medium-high upper socioeconomic level and the other two mainly a population with a medium-low socioeconomic level. A total of 160 subjects are expected to be included in the follow-up, with 80 subjects in each study group. The primary endpoint is to demonstrate that telemonitored follow-up improves functional exercise capacity compared to usual care, by assessing the distance in meters covered in the 6-minute walk test.

Interventions

DEVICEtelemonitoring

The system consists of the following elements: Professional website at the ambulatory centre, which allows: To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies. Mobile application software with the following functions: Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference. Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients

OTHERcontrol follow-up

Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles

Sponsors

Catcronic Salut SL
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

The characteristics of the interventions do not allow the study to be blinded either for the patient or for the professional. However, the analyses and surveys will be performed in a masked manner without the assigned group being identified by the investigators who carry out the examinations.

Intervention model description

Pragmatic, open-label, prospective, parallel-group study

Eligibility

Sex/Gender
ALL
Age
18 Years to 72 Years
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Patients after more than one year of an acute coronary syndrome of both sexes. * Age equal to or less than 72 years.

Exclusion criteria

* Refusal of informed consent * Advanced biological age. * Kidney failure (GFR \< 30ml/min/1.73 m2). * Liver failure (GOT \>2 times normal value). * Ejection fraction less than 50%. * Uncontrolled blood pressure (\>140/90 mmHg). * Uncontrolled heart failure. * Dissecting aortic aneurysm. * Uncontrolled ventricular tachycardia or other dangerous ventricular arrhythmias. * Aortic or mitral valve disease. * Recent systemic or pulmonary embolism. * Active or recent thrombophlebitis. * Acute infectious diseases. * Uncontrolled supraventricular arrhythmias or tachycardia. * Repeated or frequent ventricular ectopic activity. * Moderate pulmonary hypertension. * Ventricular aneurysm. * Uncontrolled diabetes, thyrotoxicosis, myxedema, * Conduction disorders such as: complete atrioventricular block. Left bundle branch block. * Wolf-Parkinson-White syndrome. * Fixed rate pacing. * Severe anaemia. * Psychoneurotic disorders. * Neuromuscular, musculoskeletal and arthritic disorders that may limit activity. may limit activity.

Design outcomes

Primary

MeasureTime frameDescription
The 6-min walk distance (6MWD)10 monthsMeters (m)

Secondary

MeasureTime frameDescription
Maximal heart rate in the six minute walk test10 monthsbeats per minute (bpm)
Total cholesterol10 monthsmg/dL
Glycosylated haemoglobin10 monthsPercentage (%)
Weight10 monthsKilograms (Kg)
Waist circumference10 monthswaist circumference change (cm)
Visceral fat10 monthspercentage (%)
High level of effort obtained from the International Physical Activity questionnaire (IPAQ) questionaire10 monthspercentage
Total score of Adherence to Mediterranean Diet obtained from the Prevention with Mediterranean Diet questionnaire (PREDIMED).10 monthsUnits. Minimum value: 0, maximum value: 14. Higher scores mean a better outcome.
Global score of emotional distress obtained from the Hospital Anxiety and Depression Scale (HADS)10 monthsUnits. Minimum value: 0, maximum value: 14. Lower scores mean a better outcome.
Anxiety subscale of emotional distress obtained from the Hospital Anxiety and Depression Scale (HADS)10 monthsUnits. Minimum value: 0, maximum value: 7. Lower scores mean a better outcome.
Depression subscale of Emotional distress obtained from the Hospital Anxiety and Depression Scale (HADS)10 monthsUnits. Minimum value: 0, maximum value: 7. Lower scores mean a better outcome.
Global index of the health-related quality of life obtained from the European Quality of Life questionnaire (EuroQol-5D)10 monthsUnits. Minimum value: 0, maximum value: 1. Higher scores mean a better outcome.
Health status obtained from the European Quality of Life questionnaire (EuroQol-5D)10 monthsUnits. Minimum value: 0, maximum value: 100. Higher scores mean a better outcome.
smoking cessation10 monthspercentage
User's experience from the System Usability Scale (SUS) score10 monthsUnits. Minimum value: 0, maximum value: 100. Higher scores mean a better outcome.
Energy expenditure obtained from the International Physical Activity questionnaire (IPAQ) questionaire10 monthsKcal/week
Body mass Index10 monthsweight and height will be combined to report BMI (kg/m\^2)
High10 monthscentimeters (cm)
Percentage expected for age and sex in the six minute walk test10 monthsPercentage
Leukocyte count10 monthWBCs per microliter
Neutrophil count10 montsNeutrophils per microliter and percentage of white blood cells
Lymphocyte count10 monthLymphocytes per microliter and percentage of white blood cells
Platelet count10 monthPlatelets per microliter
GlycA10 montsμmol/L
Small LDL particles10 monthsμmol/L
Physical activity derived from the International Physical Activity questionnaire (IPAQ)10 monthsself-reported physical activity measured in metabolic equivalents (MET-min/week) Minimum value: 0, maximum value 19,278. Higher scores mean a better outcome.
HDL cholesterol10 monthsmg/dL
LDL cholesterol10 monthsmg/dL
Non-HDL cholesterol10 monthsmg/dL
Triglycerides10 monthsmg/dL
Apolipoprotein B/Apolipoprotein A-I ratio10 monthsUnits
Cost-effectiveness analysis10 monthsnet cost divided by changes in health outcomes

Countries

Spain

Contacts

Primary ContactErnesto Dalli Peydró, MD
ernestodallip@gmail.com+34626388083
Backup ContactJuan Cosín-Sales, MD
cosin_jua@gva.es+34606338503

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026